InnoCan Pharma Corporation INNO
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.25M | 6.47M | 4.99M | 6.82M | 7.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.25M | 6.47M | 4.99M | 6.82M | 7.01M |
| Cost of Revenue | 481.00K | 575.00K | 558.00K | 631.00K | 811.00K |
| Gross Profit | 4.77M | 5.89M | 4.43M | 6.19M | 6.20M |
| SG&A Expenses | 5.29M | 6.49M | 5.19M | 6.99M | 5.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.76M | 7.25M | 5.91M | 8.04M | 6.61M |
| Operating Income | -508.00K | -786.00K | -922.00K | -1.22M | 396.00K |
| Income Before Tax | -214.00K | -822.00K | 1.59M | -1.43M | -109.00K |
| Income Tax Expenses | -64.00K | 64.00K | -262.00K | 220.00K | 206.00K |
| Earnings from Continuing Operations | -150.00K | -886.00K | 1.86M | -1.65M | -315.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 116.00K | -86.00K | 140.00K | -295.00K | -275.00K |
| Net Income | -34.00K | -972.00K | 2.00M | -1.95M | -590.00K |
| EBIT | -508.00K | -786.00K | -922.00K | -1.22M | 396.00K |
| EBITDA | -503.00K | -778.00K | -910.00K | -1.21M | 405.00K |
| EPS Basic | -0.01 | -0.22 | 0.45 | -0.43 | -0.13 |
| Normalized Basic EPS | 0.00 | -0.13 | 0.17 | -0.25 | -0.06 |
| EPS Diluted | -0.01 | -0.22 | 0.45 | -0.43 | -0.13 |
| Normalized Diluted EPS | 0.00 | -0.13 | 0.17 | -0.25 | -0.06 |
| Average Basic Shares Outstanding | 4.50M | 4.50M | 4.48M | 4.50M | 4.50M |
| Average Diluted Shares Outstanding | 4.50M | 4.50M | 4.48M | 4.50M | 4.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |